Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension for secukinumab in inflammatory arthritis and psoriasis
2020-004284-98Phase 4Active
- Sponsor
- Novartis
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of secukinumab in psoriatic arthritis (PsA), ankylosing spondylitis (AS), axial spondyloarthritis (axSpA) and 1 more, sponsored by Novartis. Primary endpoints: Serious adverse events, Adverse events and 1 more. Started Nov 2020; status: active.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)ankylosing spondylitis (AS)axial spondyloarthritis (axSpA)plaque psoriasis
Beyond the preview
Go deeper on 2020-004284-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004284-98.